Nuvalent, Inc. is creating precisely targeted therapies designed to overcome the limitations of existing therapies for clinically proven kinase targets for patients with cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.